Related Experiment Videos
The renin-angiotensin-aldosterone system as a target in coronary disease
James H O'Keefe1, Jared T Lurk, Ravindra C Kahatapitiya
1Cardiovascular Consultants, Mid America Heart Institute, Suite 2000, 4320 Wornall Road, Kansas City, MO 64111, USA. jhokeefe@cc-pc.com
Abstract:
The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the development of atherosclerosis and adverse cardiovascular events. Traditionally, the pathologic effects of the RAAS were assumed to result from vasoconstriction induced by angiotensin II, and salt and water retention due to aldosterone. However, these hormones also have powerful trophic effects, stimulating increased mass in both the arterial wall and left ventricle. In addition, angiotensin II and aldosterone predispose to vascular inflammation, thrombosis, oxidative stress, and sudden cardiac death. Therapy directed at RAAS overactivity is essential for normalizing the prognosis of most patients with atherosclerosis. An angiotensin-converting enzyme (ACE) inhibitor improves the prognosis of patients with atherosclerosis and/or diabetes even in the setting of normal baseline blood pressure. Angiotensin receptor blocking agents also improve cardiovascular structure and prognosis. Although these agents are better tolerated than ACE inhibitors, they do not appear to be as effective in reducing event rates. Aldosterone receptor blocking agents also improve cardiovascular structure, function, and prognosis. Aldosterone receptor blockers appear to provide additive benefit when used in conjunction with either an ACE inhibitor or an angiotensin receptor blocker.
Insights
Targeting the renin-angiotensin-aldosterone system (RAAS) is crucial for managing atherosclerosis. RAAS overactivity contributes to cardiovascular events, and therapies like ACE inhibitors and receptor blockers improve patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- The renin-angiotensin-aldosterone system (RAAS) is implicated in atherosclerosis and cardiovascular events.
- RAAS hormones, angiotensin II and aldosterone, exert trophic effects, promoting arterial wall and left ventricular hypertrophy.
- These hormones also contribute to vascular inflammation, oxidative stress, and thrombosis.
Purpose of the Study:
- To review the role of RAAS in atherosclerosis and cardiovascular disease.
- To evaluate the efficacy of RAAS-targeting therapies in improving cardiovascular outcomes.
Main Methods:
- Review of existing literature on RAAS pathophysiology and therapeutic interventions.
- Analysis of clinical trial data for ACE inhibitors, angiotensin receptor blockers, and aldosterone antagonists.
Main Results:
- RAAS overactivity is a key driver of atherosclerosis progression and adverse cardiovascular events.
- ACE inhibitors and angiotensin receptor blockers improve cardiovascular structure and prognosis in patients with atherosclerosis.
- Aldosterone receptor blockers offer additive benefits when combined with ACE inhibitors or angiotensin receptor blockers.
Conclusions:
- Therapy targeting RAAS overactivity is essential for managing patients with atherosclerosis.
- ACE inhibitors, angiotensin receptor blockers, and aldosterone antagonists are valuable therapeutic options.
- Combination therapy with RAAS inhibitors may provide superior cardiovascular protection.